Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.95 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.95 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.95 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.95 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.95 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.95 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.95 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.95 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.95 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.95 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.95 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.95 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.95 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.95 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.95 |
| ▸ | MAPT | P10636 | 1/20 | 0.80 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.80 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.71 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylbutanoic Acid SCHEMBL1716 | 0.98 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| Phenylbutanoic Acid SCHEMBL21219015 | 0.98 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| Phenylbutanoic Acid SCHEMBL1021513 | 0.98 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| Phenylbutanoic Acid SCHEMBL28684695 | 0.95 | HDAC1 (0.95) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| Phenylbutanoic Acid SCHEMBL29272534 | 0.95 | HDAC1 (0.95) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| Phenylbutanoic Acid SCHEMBL2010634 | 0.95 | HDAC1 (0.95) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| Phenylbutanoic Acid SCHEMBL7723613 | 0.95 | HDAC1 (0.95) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| Phenylbutanoic Acid SCHEMBL31228551 | 0.95 | HDAC1 (0.95) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| Phenylbutanoic Acid SCHEMBL29272542 | 0.95 | HDAC1 (0.95) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| Phenylbutanoic Acid SCHEMBL27900207 | 0.95 | HDAC1 (0.95) | HDAC1HDAC3HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107841532-A | Screen the method for anti-breast cancer transfer compounds and the application of related compound | 清华大学 | 2018-03-27 | — | — | CN | claimed |
| EP-3185903-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | Fundación para la Investigación Médica Aplicada (ES) | 2017-07-05 | — | — | EP | claimed |
| WO-2016030345-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2016-03-03 | — | — | WO | claimed |
| EP-1847274-A1 | Association of phenylbutyrate, ATRA and cytidine and its use in anti-tumour therapy | CIPROSA LLC - Corporate Creations Network, Inc. (US) | 2007-10-24 | — | — | EP | claimed |
| US-20250377351-A1 | METHOD FOR IDENTIFYING EFFECTIVE TREATMENTS AGAINST NEURODEGENERATIVE DISORDERS | AcuraStem Incorporated (US) | 2025-12-11 | — | — | US | disclosed |
| WO-2024211633-A1 | POLYPEPTIDE ADJUVANTS AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-10-10 | — | — | WO | disclosed |
| US-20240252594-A1 | COMBINATION THERAPY FOR NEURODEGENERATIVE DISEASES | ALETA NEUROSCIENCE LLC (US) | 2024-08-01 | — | — | US | disclosed |
| US-20240058288-A1 | DRUG COCKTAIL FOR TREATMENT OF PARKINSON'S DISEASE, LEWY BODY DISEASE AND MULTIPLE SYSTEM ATROPHY | ALETA NEUROSCIENCE LLC (US) | 2024-02-22 | — | — | US | disclosed |
| US-20240041807-A1 | COMBINATION THERAPY TO TREAT UREA CYCLE DISORDERS | BAYLOR COLLEGE OF MEDICINE | 2024-02-08 | — | — | US | disclosed |
| US-11819483-B2 | Combination therapy to treat urea cycle disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230181504-A1 | COMBINATION THERAPY TO TREAT UREA CYCLE DISORDERS | BAYLOR COLLEGE OF MEDICINE | 2023-06-15 | — | — | US | disclosed |
| WO-2023042178-A2 | COMBINATION THERAPY FOR NEURODEGENERATIVE DISEASES | ALETA NEUROSCIENCE, LLC (US) | 2023-03-23 | — | — | WO | disclosed |
| EP-1334358-A1 | TARGETING CELLS HAVING MAD2 MUTATION FOR TREATMENT AND/OR PREVENTION OF DISEASE | Regents of the University of California (US) | 2003-08-13 | — | — | EP | disclosed |
| WO-2003044525-A1 | TARGETING CELLS HAVING MAD2 MUTATION FOR TREATMENT AND/OR PREVENTION OF DISEASE | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-05-30 | — | — | WO | disclosed |
| WO-2003042411-A2 | USE OF MUTATIONS OF MEC-1 AND ITS RELATED GENES IN THE IDENTIFICATION OF COMPOUNDS FOR TREATMENT OF DISEASE | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2003-05-22 | — | — | WO | disclosed |
| WO-2003022253-A1 | DOSAGE FORMS HAVING PROLONGED ACTIVE INGREDIENT RELEASE | LUNAMED AG (CH) | 2003-03-20 | — | — | WO | disclosed |
| EP-1291015-A1 | Dosage forms having prolonged active ingredient release | Lunamed AG (CH) | 2003-03-12 | — | — | EP | disclosed |
| CN-1369297-A | Mixture of four ginseng for promoting blood circulation and preparation method thereof | LIU FENGYI (CN) | 2002-09-18 | — | — | CN | disclosed |
| US-20020054912-A1 | Microparticles | BOARD OF TRUSTEES OF UNIVERSITY OF LLINOIS | 2002-05-09 | — | — | US | disclosed |
| WO-2002013786-A2 | METHOD OF FORMING MICROPARTICLES | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240058288-A1 | DRUG COCKTAIL FOR TREATMENT OF PARKINSON'S DISEASE, LEWY BODY DISEASE AND MULTIPLE SYSTEM ATROPHY | BAG3, BAG2, PHB1 | HDAC1 2195/4885HDAC3 1561/4885HDAC2 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.